Initiation of Medical Therapy for Heart Failure Patients According to Kidney Function: A Danish Nationwide Study

References

• Smith DH, Thorp ML, Gurwitz JH, et al. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE study. Circ Cardiovasc Qual Outcomes. 2013;6:333–342. doi:10.1161/CIRCOUTCOMES.113.000221
   PubMed Web of Science ®Google Scholar
• Damman K, Valente MAE, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35:455–469. doi:10.1093/eurheartj/eht386
   PubMed Web of Science ®Google Scholar
• McCullough PA, Amin A, Pantalone KM, Ronco C. Cardiorenal nexus: a review with focus on combined chronic heart and kidney failure, and insights from recent clinical trials. J Am Heart Assoc. 2022;11. doi:10.1161/JAHA.121.024139
   Web of Science ®Google Scholar
• Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671–678. doi:10.1161/CIRCULATIONAHA.105.580506
   PubMed Web of Science ®Google Scholar
• Patel RB, Fonarow GC, Greene SJ, et al. Kidney function and outcomes in patients hospitalized with heart failure. J Am Coll Cardiol. 2021;78:330–343. doi:10.1016/j.jacc.2021.05.002
   PubMedGoogle Scholar
• Beldhuis IE, Lam CSP, Testani JM, et al. Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease. Circulation. 2022;145:693–712. doi:10.1161/CIRCULATIONAHA.121.052792
   PubMed Web of Science ®Google Scholar
• Pedersen CB. The Danish civil registration system. Scand J Public Health. 2011;39:22–25. doi:10.1177/1403494810387965
   PubMed Web of Science ®Google Scholar
• Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register. Scand J Public Health. 2011;39:30–33. doi:10.1177/1403494811401482
   PubMed Web of Science ®Google Scholar
• Wallach Kildemoes H, Toft Sørensen H, Hallas J. The Danish national prescription registry. Scand J Public Health. 2011;39:38–41. doi:10.1177/1403494810394717
   PubMed Web of Science ®Google Scholar
• Hommel K, Rasmussen S, Madsen M, Kamper AL. The Danish Registry on regular dialysis and transplantation:completeness and validity of incident patient registration. Nephrol Dial Transplant. 2010;25:947–951. doi:10.1093/ndt/gfp571
   PubMed Web of Science ®Google Scholar
• Arendt JFH, Hansen AT, Ladefoged SA, et al. Existing data sources in clinical epidemiology: laboratory information system databases in Denmark. Clin Epidemiol. 2020;12:469–475. doi:10.2147/CLEP.S245060
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612. doi:10.7326/0003-4819-150-9-200905050-00006
   PubMed Web of Science ®Google Scholar
• Hjertesvigt D. Arbejdsgruppe for Kronisk hjertesvigt. Dansk Cardiol Selsk. 2014;3:15.
   Google Scholar
• Gilbert T, Neuburger J, Kraindler J, et al. Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study. Lancet. 2018;391:1775–1782. doi:10.1016/S0140-6736(18)30668-8
   PubMed Web of Science ®Google Scholar
• Chan M; World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Geneva, Switzerland: World Health Organization; 2011:1–6. Available from: http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Haemoglobin+concentrations+for+the+diagnosis+of+anaemia+and+assessment+of+severity#1. Accessed July 5, 2023.
   Google Scholar
• Biswas M, Davies JS. Hyponatraemia in clinical practice. Postgrad Med J. 2007;83:373–378. doi:10.1136/pgmj.2006.056515
   PubMed Web of Science ®Google Scholar
• Madelaire C, Gustafsson F, Køber L, et al. Identification of patients with new-onset heart failure and reduced ejection fraction in Danish administrative registers. Clin Epidemiol. 2020;12:589–594. doi:10.2147/CLEP.S251710
   PubMed Web of Science ®Google Scholar
• Butt JH, Jhund PS, Belohlávek J, et al. Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation. 2022;146:1210–1224. doi:10.1161/CIRCULATIONAHA.122.061754
   PubMed Web of Science ®Google Scholar
• Butt JH, Dewan P, Merkely B, et al. Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction A post hoc analysis of the DAPA-HF trial. Ann Intern Med. 2022;175:820–830. doi:10.7326/M21-4776
   PubMed Web of Science ®Google Scholar
• Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018;72:351–366. doi:10.1016/j.jacc.2018.04.070
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321. doi:10.1056/NEJMoa030207
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21. doi:10.1056/NEJMoa1009492
   PubMed Web of Science ®Google Scholar
• McMurray J, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008. doi:10.1056/NEJMoa1911303
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413–1424. doi:10.1056/NEJMoa2022190
   PubMed Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–1461. doi:10.1056/NEJMoa2107038
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089–1098. doi:10.1056/NEJMoa2206286
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:E895–E1032. doi:10.1161/CIR.0000000000001063
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–3726. doi:10.1093/eurheartj/ehab368
   PubMed Web of Science ®Google Scholar
• Kotecha D, Gill SK, Flather MD, et al. Impact of renal impairment on beta-blocker efficacy in patients with heart failure. J Am Coll Cardiol. 2019;74:2893–2904. doi:10.1016/j.jacc.2019.09.059
   PubMed Web of Science ®Google Scholar
• Flather MD, Shibata MC, Coats AJS, et al. FASTTRACK Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–225. doi:10.1093/eurheartj/ehi115
   PubMed Web of Science ®Google Scholar
• Khan MS, Segar MW, Usman MS, et al. Frailty, guideline-directed medical therapy, and outcomes in HFrEF: from the GUIDE-IT trial. JACC Hear Fail. 2022;10:266–275. doi:10.1016/j.jchf.2021.12.004
   PubMed Web of Science ®Google Scholar
• Butt JH, Dewan P, Jhund PS, et al. Sacubitril/valsartan and frailty in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2022;80:1130–1143. doi:10.1016/j.jacc.2022.06.037
   PubMed Web of Science ®Google Scholar
• Eschalier R, McMurray JJV, Swedberg K, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (eplerenone in mild patients hospitalization and survival study in heart failure). J Am Coll Cardiol. 2013;62:1585–1593. doi:10.1016/j.jacc.2013.04.086
   PubMed Web of Science ®Google Scholar
• Jonsson A, Norberg H, Bergdahl E, Lindmark K. Obstacles to mineralocorticoid receptor antagonists in a community-based heart failure population. Cardiovasc Ther. 2018;36:e12459. doi:10.1111/1755-5922.12459
   PubMed Web of Science ®Google Scholar
• Matsushita K, Mahmoodi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012;307:1941–1951. doi:10.1001/jama.2012.3954
   PubMed Web of Science ®Google Scholar